
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Planning fundamentals map the route to increased worldwide market share.
over 25 years ago
The Power of Public Relationsover 25 years ago
Market Research 101over 25 years ago
How to Win Friends and Influence R&Dover 25 years ago
Working with an Agencyover 25 years ago
A Strategic Overviewover 25 years ago
The Regulatory Environment





